Kanger (0170)
Kanger (0170), The Bamboo Flooring And Related Products Company Is Trying Hard To Secure Covid-19 Vaccines Business
Kanger International Bhd, an investment holding company, engages in the research, development, manufacture, and trade of bamboo flooring and related products in the People's Republic of China. It operates the business across North America, Europe, and Asia. By second halve of the year 2020, Kanger started to explore a plan for a new venture in business: to distribute the Covid-19 vaccines manufactured by Sinopharm in Malaysia. Kanger has tried hard to secure this Covid-19 vaccines business as this new business expected to bring a better results for the company.
THE CURRENT DEVELOPMENT OF KANGER'S BAMBOO BUSINESS
Kanger (0170) is a "green" building materials provider, specialising in the manufacturing and trading of bamboo flooring and related products for the residential and commercial markets under its brands 'Kanger' and 'KAR Masterpiece' as well as OEM at the request of its customers. In additional, it also sell strand woven bamboo planks, a semi-finished product from its strand woven bamboo flooring manufacturing process, to furniture and building materials manufacturers as raw materials for their production. The bamboo flooring and related products business is still running well as can be seen at these websites:
1. https://krbamboo.en.china.cn/
2. https://shenzhenkanger1.sell.everychina.com/
3. https://www.tradewheel.com/co/shenzhen-kanger-bamboo-wood-45509/products/
On September 2020, Kanger planned to strengthen its bamboo products business. Kanger is on target to become the world’s largest producer of bamboo products with the commencement of a new high-tech bamboo processing plant and R&D centre, which was developed in collaboration with the local government of Jingzhou, Hunan Province, China. Kanger has accumulated vast experience and strong know-how of the bamboo industry, having been involved in the bamboo processing business over the past 16 years.
(Source: https://www.theborneopost.com/2020/09/10/kanger-aims-to-be-worlds-largest-bamboo-products-producer/)
EFFORTS BY THE COMPANY TO SECURE COVID-19 VACCINE BUSINESS
There are some efforts taken by Kanger to make sure they will successfully enter the Covid-19 distribution business. The chronological list (by date) of the efforts taken are listed below:
1. The Covid-10 vaccine started, when Kanger has entered into a proxy agreement with Shenzhen Public Health Technology Co, Ltd (SZPHT) to procure dealership status from China National Biotec Group Company Ltd (CNBG), which is a subsidiary of China National Pharmaceutical Group Corp (Sinopharm) and distributing it in Southeast Asia.
(Remarks: This agreement has been lapsed because it is only valid until October 8, 2020)
2. Kanger has entered a collaboration agreement with China-based Sinopharm Group Hunan Changde Medical Co Ltd (Sinopharm Group) for the distribution of Covid-19 vaccines developed by China National Biotech Group Company (CNBG) in Malaysia.
Under the agreement, Sinopharm Group has appointed KIB as the sole distributor for the vaccines, medical devices and products in Malaysia. KIB will also undertake the marketing and promotion of Sinopharm Group's products in Malaysia, however, both parties will sign a separate agreement in regards to specific product category, price, purchase price and payment method.
(Remarks: This agreement shall take effect for a period of three years effective from 25 September 2020 until 24 September 2023)
3. Kanger revealed their final phase of discussion to be a distributor of Covid-19 vaccines for private sector in Malaysia.
Source: https://www.msn.com/en-my/news/berita/kanger-bincang-jadi-pengedar-vaksin-covid-19/ar-BB1bgXxB
4. Kanger International Bhd has received the nod from the National Institutes of Biotechnology Malaysia (NIBM) to distribute Covid-19 vaccines and medical equipment in Malaysia.
5. Kanger International Bhd will receive 10,000 doses of a Covid-19 vaccine developed by state-owned China National Pharmaceutical Group Corp (Sinopharm) for trial purposes.
(Remarks: The first batch of vaccines is expected to arrive in Malaysia on May 2021).
6. Kanger Donates RM200,000 To Sabah In Efforts To Combat Covid-19
(Remarks: Is it a type of lobby? )
7. Kanger International offers 5,000 doses of Sinopharm Covid-19 vaccine to Sabah
(Remarks: Is it another type of lobby? )
8. MOU with Sabah State Government to obtain Sinopharm Covid-19 vaccines
(Remarks: Will the MOU with Sabah State Government helps the company to obtain approval for Sinopharm Covid-19 vaccine from the government through the National Pharmaceutical Regulatory Agency Negara (NPRA)? )
WHAT IS THE EXPECTED RESULTS?
Based on these reports:
Report 1: The Sinopharm Covid-19 vaccine is in the process of being approved in Malaysia, including by the National Pharmaceutical Regulatory Agency (NPRA).
“We will ensure that we obtain the required approvals from relevant authorities before we commence distribution of the Sinopharm vaccines.
“Once approvals are obtained, the people of Sabah will be one of the early recipients of the Sinopharm vaccines,” Kuah said.
Report 2: Kanger International executive director Steven Kuah told reporters that, “the process of registering the Sinopharm vaccine (with NPRA) has started and we hope to receive some good news on its approval soon.”
Report 3: Covid-19: Those who want to bring in Sinopharm vaccine can register it with NPRA, says Khairy.
Report 4: Supplies through Putrajaya is just one of the options available, and that state governments could source their own as long as they are approved by the National Pharmaceutical Regulatory Agency (NPRA) – says Khairy
(Source: https://malaysia.news.yahoo.com/khairy-says-okay-states-direct-094230051.html )
Report 5: PM says anyone can buy Covid-19 vaccines, as long as approved by NPRA.
Report 6: The states are free to negotiate with drug makers Moderna and Sinopharm, whose vaccines have been approved by the World Health Organization . Khairy said that as long as the vaccines have been given the green light by the National Pharmaceutical Regulatory Agency, the states are free to procure them.
Therefore, we are hoping that, sooner Kanger will be successful in securing their objective to be an approved Covid-19 vaccines distributor in Malaysia.
** DISCLAIMER: I wrote this article based on my research from www.bursamalaysia.com and information reported on the web. All information given should not be considered as an investment advice. Please do your own analysis or consult your qualified financial advisor for advice. All information is not a buy call or a sell call in any securities transactions.
Related Stocks
| Chart | Stock Name | Last | Change | Volume |
|---|
More articles on Kanger (0170)
A Glance At Positivities From The Kanger (0170) Annual Report 2021
Created by MZM2511 | Aug 31, 2021
Is It True That The Process of Registering The Sinopharm Vaccine (With NPRA) Has Started?
Created by MZM2511 | Jun 02, 2021
Discussions
1 person likes this. Showing 11 of 11 comments
My opinion kanger will have bright future..... if sucsess it will be next bintai and solutn
2021-06-04 12:18
UPDATED NEWS...
KJ sahkan ada pihak tempatan cuba daftar vaksin Sinopharm
Menteri Penyelaras Program Imunisasi COVID-19 Kebangsaan sahkan terdapat beberapa pihak tempatan yang sedang cuba mendaftarkan vaksin Sinopharm dihasilkan syarikat farmaseutikal dari China. Vaksin sinopharm tidak termasuk di dalam Program Imunisasi COVID-19 Kebangsaan (PICK). Kata Khairy Jamaluddin, perkara berkenaan adalah dibenarkan dan pihaknya mengalu-alukan perkara tersebut. (May 21, 2021)
Sumber: https://www.astroawani.com/video-malaysia/covid-19-kj-sahkan-ada-pihak-tempatan-cuba-daftar-vaksin-sinopharm-1905361
2021-06-06 04:39
Setakat ini, katanya, Malaysia hanya meluluskan penggunaan vaksin Pfizer, Sinovac dan AstraZeneca sedangkan Pertubuhan Kesihatan Dunia (WHO) telah menyenaraikan Johnson & Johnson, Moderna dan Sinopharm untuk kegunaan kecemasan di seluruh dunia.- Hishammuddin Hussein
Sumber: https://www.malaysiakini.com/news/578764
2021-06-14 08:16
An update on the prospect of Kanger to be involved as the distributor of Sinopharm Covid-19 vaccine in Malaysia:
Report 1: 9 March 2021.
Kanger International Bhd will receive 10,000 doses of a Covid-19 vaccine developed by state-owned China National Pharmaceutical Group Corp (Sinopharm) for trial purposes.
In a bourse filing today, the group said the 10,000 doses of the vaccine will be for trial purposes and that it will be getting the necessary approvals from the relevant authorities.
“The first batch of vaccines is expected to arrive in May 2021,” Kanger stated.
Sinopharm has Covid-19 vaccine candidates that are undergoing stage 3 clinical trials
Source: https://www.theedgemarkets.com/article/kanger-receive-10000-doses-sinopharm-covid19-vaccine%C2%A0-may-trial-purposes
Report 2: 21 May2021.
The government is open to any party that has the capability and clinical data of the Sinopharm Covid-19 vaccine to register it with the National Pharmaceutical Regulatory Agency (NPRA), says Khairy Jamaluddin (pic).
The National Covid-19 Immunisation Programme coordinating minister said that this DID NOT HAVE TO GO THROUGH PHARMANIAGA, the local registration product holder for the Sinovac vaccine.
He said there were several parties interested in bringing the Sinopharm vaccine from China.
“It can go through anybody else who wants to try and bring in the vaccine. It can be registered with the NPRA,” he said in a video late Thursday (May 20) to address several allegations made by Opposition leader Datuk Seri Anwar Ibrahim about the immunisation programme.
Source: https://mywinet.com/covid-19-those-who-want-to-bring-in-sinopharm-vaccine-can-register-it-with-npra-says-khairy/
Report 3: 27 May2021.
“the process of registering the Sinopharm vaccine (with NPRA) has started and we hope to receive some good news on its approval soon.” Source: https://www.freemalaysiatoday.com/category/nation/2021/05/27/sabah-signs-mou-with-private-firm-to-obtain-sinopharm-vaccine/
MY FINDINGS:
1. Kanger planned to bring Sinopharm Covid-19 vaccine for trial purposes.
2. Until 21 May 2021, the Sinopharm Covid-19 vaccine was not registered with NPRA yet.
3. There will be a big probability that the report by Kanger official is true. The company has started to register the said vaccine with NPRA.
2021-06-22 08:30
On the Sputnik Covid-19 vaccine produced by Russia, Khairy said that Duopharma Biotech Bhd’s wholly-owned subsidiary, Duopharma (M) Sdn Bhd (DMSB), which holds the distribution rights to the product, has three months to register the vaccine with the National Pharmaceutical Regulatory Agency (NPRA), after inking an agreement with the government earlier this month.
He said that the NPRA still requires further information on the vaccine.
“However, NPRA also said that it would simplify the registration process if Sputnik gets emergency use (status) from the World Health Organisation (WHO). Sputnik has not received the EUL from WHO yet,” he said, referring to the Emergency Use Listing.
Source: https://www.malaymail.com/news/malaysia/2021/06/21/khairy-cansino-vaccine-to-arrive-in-malaysia-next-month-no-updates-yet-on-j/1983852
2021-06-22 09:48
“However, NPRA also said that it would simplify the registration process if Sputnik gets emergency use (status) from the World Health Organisation (WHO).
--------------------
I want to stress on this.
If the Sinopharm was truly just registered with NPRA, the process of approval should be more shorter in time compared with the vaccine candidate which not been approved by WHO yet.
Note: Sinopharm vaccine has been approved by WHO,
2021-06-22 09:48
Khairy also mentioned that Covid-19 vaccines will enter the private market by August. He said that private vaccination will help the government ramp up the national Covid-19 vaccination programme, as those who are able to pay for the vaccines will be able to do so.
“I also anticipate by about August, we will have a private vaccine market. So right now, it’s difficult for private because vaccines are in short supply. But by August, I think that there will be some companies who will be approved to bring in some private vaccines from China. I know Sinopharm and all that are going to be registered here,” Khairy added.
“That’s also part of the plan. I’ve been talking to the Ministry of Health to ensure that the private market by August can take off to help us.”
Source: https://codeblue.galencentre.org/2021/06/24/khairy-projects-40-population-fully-vaccinated-by-end-august/
2021-06-24 19:00
Dr Noor Hisham: NPRA set to announce Sinopharm’s inclusion in Covid-19 immunisation plan
“Tomorrow the NPRA will meet and we will consider the Sinopharm vaccine, which was approved by the World Health Organisation.
“Their company just sent their dossiers to us, and in less than a month we have evaluated and will give our decision on the conditional approval tomorrow,” he said.
Source: https://malaysia.news.yahoo.com/dr-noor-hisham-npra-set-111805262.html
2021-07-15 20:58
The Board of Directors of Kanger (“Company”) wishes to announce that Kanger Medical International Sdn. Bhd., a wholly-owned subsidiary of the Company had, on 19 July 2021 entered into Head of Agreement with Sparmak Medical Equipment Trading LLC for purchase of inactivated SARS-COV-2 Vaccines (Vero Cell) vaccine developed by Beijing Institute of Biological Products Co. Ltd., an affiliate of SINOPHARM CNBG.
Please refer to the full announcement as attached.
This announcement is dated 19 July 2021.
Source: https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3176295
4.1 Quantity and specification of the Products
Quantity: Five Million (5,000,000) doses with an option to buy an additional Five Million (5,000,000) doses.
Specification: SARS COV-2 vaccine (Vero cell) inactivated, 6.5 U/0.5ml in prefilled syringe or vial (as per availability) and pack size either 2 doses per vial per box or Single dose per vial per box (as per availability). The Product is manufactured by Gulf Pharmaceutical Industries Julphar in the United Arab Emirates (HAYAT-VAX), i.e. G42 Medications Trading LLC (“Manufacturer”).
2021-07-19 13:41
Earlier this year, Sinopharm entered into a joint venture with UAE-based G42 to produce the Sinopharm Covid-19 vaccines in the country under the Hayat-Vax brand.
The made-in-UAE vaccine was the first Covid-19 vaccine to be produced in the Arab world.
"The Hayat-Vax vaccine is essentially the same Sinopharm Covid-19 vaccine, manufactured in the UAE. Hence, we are confident that it will be well-received and accepted by the Malaysian people as an effective vaccine towards the global fight against the Covid-19 pandemic," said Kuah.
Kanger has also been authorised by G42 to be the product registration holder and distributor of the Hayat-Vax vaccine in Malaysia.
On behalf of G42 Medications, Kanger said it had submitted applications to obtain the required approvals from the National Pharmaceutical Regulatory Agency for the Hayat-Vax vaccine to be used in Malaysia.
2021-07-19 17:39
Post a Comment
Featured Posts
Open a Moomoo Account Today and Win an Apple iPad Air*!
MQ Trading Signals
Time
Signal
Duration
Type
2024-05-03 12:05:00
EMA 5
5 Mins
BUY
2024-05-03 11:45:00
EMA 5
5 Mins
SELL
2024-05-03 11:40:00
EMA 5
10 Mins
SELL
2024-05-03 11:30:00
EMA 5
30 Mins
SELL
2024-05-03 11:10:00
EMA 5
10 Mins
BUY
Apps
Top Articles
1
3
博傻理论
4
Good Articles to Share
5
6
THE INVESTMENT APPROACH OF CALVIN TAN
MKHOP (5139) What Is Its Current Forward P/E and Intrinsic Value, Calvin Tan
8
BFM Podcast
#
Stock
Score
Daily Stocks
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Featured Advertisers / Partners
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
MZM2511
1. Perjanjian sebagai SOLE DISTRIBUTOR yang dilantik untuk 3 tahun oleh Sinopharm dah ada - SETTLE
Sumber: https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3092107
2. MOU untuk wakil distributor bagi pihak Kanger dah ada iaitu Zuellig Pharma - SETTLE
Sumber:
1. https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3154098
2. https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3137884
Nota: Kanger will collaborate with ZP to facilitate the import, warehousing, and
distribution of Covid-19 vaccines in Malaysia. Kanger will receive 10,000 doses of a Covid-19 vaccine developed by state-owned China National Pharmaceutical Group Corp (Sinopharm) for trial purposes. The first batch of vaccines is expected to arrive in Malaysia on May 2021).
3. MOU untuk saluran jualan vaksin ke kilinik swasta di Malaysia dah ada iaitu KSport - SETTLE
Sumber:
1. https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3154097
2. https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3137884
SEKARANG TUNGGU UNTUK PROSES APPROVAL OLEH KERAJAAN DAN NPRA SAHAJA.
2021-06-04 12:03